{
    "sponsor_name": "",
    "study_acronym": "",
    "tested_imp": "apixaban",
    "comparative_drug": "dalteparin",
    "study_type": "",
    "interventional_study_phase": "",
    "study_design": "",
    "aim_of_study": "To evaluate the consistency of treatment effects (major bleeding and efficacy) of apixaban versus dalteparin in various patient subgroups with cancer-associated VTE.",
    "target_disease": "cancer-associated venous thromboembolism (VTE)",
    "type_of_randomization": "",
    "randomization_stratification": [
        "cancer type",
        "cancer treatment",
        "incidental vs symptomatic VTE"
    ],
    "apixaban_dosing": "",
    "dalteparin_dosing": "",
    "apixaban_supply_form": "",
    "dalteparin_supply_form": "",
    "scheduled_visits": [],
    "primary_efficacy_outcome": "",
    "secondary_efficacy_outcomes": [],
    "primary_safety_outcome": "major bleeding",
    "secondary_safety_outcomes": [],
    "maximum_sample_size_per_arm": 0,
    "recommended_inclusion_criteria": [],
    "recommended_exclusion_criteria": []
}